Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis asset VRG-145 BUDAPEST, HUNGARY, January 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results